The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus

Leukemia

Volumn 21, Issue 12, 2007, Pages 2428-2432

  Burgstaller, S ^a   Kreil, S ^a   Waghorn, K ^a   Metzgeroth, G ^b   Preudhomme, C ^c   Zoi, K ^d   White, H ^a   Cilloni, D ^e   Zoi, C ^d   Brito Babapulle, F ^f   Walz, C ^b   Reiter, A ^b   Cross, N C P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF MANNHEIM   (Germany)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^e UNIVERSITY OF TURIN   (Italy)

^f EALING HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIP1L1 PROTEIN; HYBRID PROTEIN; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR; INTERLEUKIN 5 RECEPTOR ALPHA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; EUROPE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; POLYMORPHIC LOCUS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 36348971680     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404977     Document Type: Article

References (17)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
3. Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn J-E, Lai J-L, Hachulla E et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005; 19: 792-798.
4. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliot MA et al. FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30: 965-970.
5. Jovanovic J, Score J, Waghorn K, Dilloni D, Gottardi E, Metzgeroth G et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukaemia. Blood, 2007; 109: 4635-4640.
6. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003; 3: 459-469.
7. Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukaemia (CEL)-like disease. Blood 2006; 107: 4071-4079.
8. Cheong HS, Kim LH, Park BL, Choi YH, Park HS, Hong SJ et al. Association analysis of interleukin 5 receptor alpha subunit (IL5RA) polymorphisms and asthma. J Hum Genet 2005; 50: 628-634.
9. Ryan AW, Thornton JM, Brophy K, Daly JS, McLoughlin RM, O'Morain C et al. Chromosome 5q candidate genes in coeliac disease: Genetic variation at IL4, IL5, IL9, IL13, IL17B and NR3C1. Tissue Antigens 2005; 65: 150-155.
10. Yamamoto N, Sugiura H, Tananka K, Uehara M. Heterogeneity of interleukin 5 genetic background in atopic dermatitis patients: Significant difference between those with blood eosinophilia and normal eosinophil levels. J Dermatol Sci 2003; 33: 121-126.
11. Kouriba B, Chevillard C, Bream JH, Argiro L, Dessein H, Arnaud V et al. Analysis of the 5q31-q33 locus shows an association between IL13-1055C/T IL-13-591A/G polymorphisms and Schistosoma haematobium infections. J Immunol 2005; 174: 6274-6281.
12. Choi EH, Lee HJ, Yoo T, Chanock SJ. A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J Infect Dis 2002; 186: 1207-1211.
13. van Dongen JJM, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect of lymphoproliferations: Report of the BIOMED-2 Concerted Action BMHCT98-3936. Leukemia 2003; 17: 2257-2317.
14. White HE, Durston VJ, Seller A, Fratter C, Harvey JF, Cross NCP. Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing. Genet Test 2005; 9: 190-199.
15. Cross NCP, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
16. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.